FGF21 and metabolic dysfunction-associated steatotic liver disease: MASLD associated with differential expression of key indicators of bone loss: decreased hepatic igf1 and cyp2r1, increased hepatic fgf21, ctgf, and anxa2, decreased skeletal bglap, runx2, and postn, and increased skeletal pparg.